Stocks
GlaxoSmithKline (GSK) Debt/EBITDA US GAAP (year values) |
|||||||||
| 2022 | 2023 | 2023 | 2024 | 2025 | LTM ? | CAGR 5 years ? | |||
| Debt/EBITDA | 1.49 | 1.36 | 1.80 | 1.99 | 1.37 | 1.83 | |||
| Changes by years, y/y, % | -2% | -8% | +32% | +10% | -31% | -11.7% | |||
GlaxoSmithKline. Debt/EBITDA
GlaxoSmithKline. Debt/EBITDA, changes, %
GlaxoSmithKline (GSK) Debt/EBITDA US GAAP (quarter values) |
||||||||
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | LTM ? | |||
| Debt/EBITDA | 2.34 | 2.19 | 1.80 | 1.23 | 1.83 | 1.83 | ||
| Changes by years, y/y, % | +66% | +56% | -6% | -38% | -22% | |||
| Changes by quarters, q/q, % | +18% | -7% | -18% | -32% | +48% | |||
